Heart valve disease affects millions of people worldwide and, when left untreated, can lead to heart failure, stroke, and death. Surgical and catheter-based valve interventions have advanced dramatically over the past two decades, offering patients options that were unimaginable a generation ago. Shanghai has developed into one of Asia's leading centers for cardiac surgery, with hospitals performing thousands of valve procedures annually using the latest open, minimally invasive, and transcatheter techniques. For international patients, the combination of clinical expertise, modern infrastructure, and significantly lower costs makes Shanghai a compelling destination for valve surgery.
Understanding Heart Valve Disease
The heart has four valves — mitral, aortic, tricuspid, and pulmonary — that regulate blood flow through the cardiac chambers. Valve disease occurs when one or more valves fail to open or close properly, disrupting normal blood flow. The two fundamental mechanisms are:
- Stenosis: The valve leaflets become thickened, calcified, or fused, narrowing the valve opening and restricting forward blood flow. The heart must work harder to pump blood through the narrowed orifice, eventually leading to hypertrophy and failure.
- Regurgitation (insufficiency): The valve fails to close completely, allowing blood to leak backward. This volume overload progressively dilates and weakens the heart.
The most clinically significant valve conditions are:
- Aortic Stenosis (AS): The most common valve disease in adults over 65 in Western countries. Calcific degeneration of the aortic valve leaflets progressively narrows the outflow tract. Severe symptomatic AS carries a poor prognosis without intervention — median survival of 2–3 years after symptom onset.
- Mitral Regurgitation (MR): The most common valve disease globally. Can be primary (degenerative, due to mitral valve prolapse or leaflet pathology) or secondary/functional (due to left ventricular dilation or dysfunction). Chronic severe MR leads to progressive left ventricular remodeling and heart failure.
- Mitral Stenosis (MS): Most commonly caused by rheumatic heart disease, which remains prevalent in parts of Asia, Africa, and South America. Progressive narrowing of the mitral valve orifice impairs left ventricular filling and causes pulmonary hypertension.
- Aortic Regurgitation (AR): Backflow of blood from the aorta into the left ventricle during diastole. Causes include bicuspid aortic valve, aortic root dilation, infective endocarditis, and rheumatic disease.
- Tricuspid Regurgitation (TR): Often secondary to left-sided heart disease and pulmonary hypertension. Increasingly recognized as an independent contributor to morbidity and mortality, and now more frequently addressed surgically.
Diagnosis and Pre-Operative Assessment
Accurate diagnosis and risk stratification are essential before any valve intervention. The standard diagnostic workup includes:
- Transthoracic Echocardiography (TTE): The cornerstone of valve disease assessment. Provides detailed information on valve morphology, severity of stenosis or regurgitation, ventricular size and function, and pulmonary pressures.
- Transesophageal Echocardiography (TEE): Higher-resolution imaging of valve structures, particularly useful for mitral valve assessment and pre-procedural planning for transcatheter interventions.
- Cardiac CT: Essential for TAVR planning — provides precise measurements of the aortic annulus, root geometry, and vascular access routes. Also used to assess coronary anatomy and aortic calcification.
- Coronary Angiography: Required before most open valve surgeries to assess for concomitant coronary artery disease that may need to be addressed simultaneously.
- Cardiac MRI: Provides quantitative assessment of regurgitant volumes, ventricular function, and myocardial fibrosis — increasingly used in complex cases.
Risk assessment tools such as the Society of Thoracic Surgeons (STS) score and EuroSCORE II are used to estimate operative mortality and guide the choice between surgical and transcatheter approaches.
Surgical Valve Replacement
Open heart surgery remains the gold standard for many valve conditions, particularly in younger patients and those with complex multi-valve disease. The procedure is performed under general anesthesia with cardiopulmonary bypass (the heart-lung machine), which temporarily takes over the function of the heart and lungs while the surgeon works on the valve.
Mechanical vs. Biological Prostheses
When a valve cannot be repaired and must be replaced, the surgeon implants a prosthetic valve. The two main categories are:
- Mechanical valves: Made from pyrolytic carbon. Extremely durable — designed to last a lifetime. The major drawback is the requirement for lifelong anticoagulation with warfarin, which carries bleeding risks and requires regular INR monitoring. Preferred in younger patients (<60–65 years) who can tolerate anticoagulation.
- Biological (bioprosthetic) valves: Made from porcine (pig) or bovine (cow) pericardial tissue, mounted on a stent. Do not require long-term anticoagulation (only 3 months post-implant in most cases). The trade-off is limited durability — typically 10–20 years depending on patient age and valve position. Preferred in older patients (>65–70 years) or those with contraindications to anticoagulation. Younger patients choosing a bioprosthesis should understand they may require re-intervention.
The choice between mechanical and biological valves is individualized and should involve a detailed discussion of lifestyle, anticoagulation tolerance, and long-term re-intervention risk.
Minimally Invasive Valve Surgery
Traditional open heart surgery requires a full median sternotomy — splitting the breastbone. Minimally invasive approaches have been developed to reduce surgical trauma, blood loss, pain, and recovery time:
- Mini-sternotomy: A partial upper or lower sternal incision provides access to the aortic valve with less disruption than a full sternotomy.
- Right mini-thoracotomy: A small incision between the ribs on the right side of the chest provides excellent access to the mitral valve. This approach avoids sternal division entirely, resulting in faster recovery and better cosmesis.
- Robotic-assisted valve surgery: Using the da Vinci robotic system, surgeons can perform mitral valve repair through tiny port incisions with enhanced visualization and precision. Available at select Shanghai centers.
Shanghai's cardiac surgery departments at Zhongshan Hospital, Shanghai Chest Hospital, and Ruijin Hospital have extensive experience with minimally invasive valve surgery. Hospital stays for minimally invasive procedures are typically 5–8 days, compared to 7–12 days for conventional open surgery.
Mitral Valve Repair vs. Replacement
For mitral regurgitation, valve repair is strongly preferred over replacement whenever technically feasible. Repair preserves the native valve apparatus, maintains better left ventricular geometry and function, avoids the need for a prosthesis (and its associated risks), and offers superior long-term outcomes. Repair durability at experienced centers exceeds 90% freedom from reoperation at 10 years for degenerative MR.
Repair techniques include leaflet resection, chordal replacement with Gore-Tex neochords, annuloplasty ring implantation, and commissuroplasty. The complexity of the repair depends on the underlying pathology — posterior leaflet prolapse is generally more straightforward than anterior or bileaflet prolapse.
The decision to repair versus replace should ideally be made at a high-volume center with demonstrated repair rates exceeding 90% for degenerative disease. Shanghai's leading cardiac surgery programs meet this standard.
Transcatheter Aortic Valve Replacement (TAVR)
TAVR — also known as TAVI (Transcatheter Aortic Valve Implantation) — has revolutionized the treatment of aortic stenosis. Rather than open surgery, a collapsible bioprosthetic valve is delivered via catheter — most commonly through the femoral artery in the groin — and deployed within the diseased native aortic valve, pushing the calcified leaflets aside.
Originally developed for patients deemed too high-risk for surgery, TAVR has now been validated across all surgical risk categories, including low-risk patients, based on landmark trials (PARTNER 3, Evolut Low Risk). It is increasingly the preferred approach for older patients (>75 years) with severe symptomatic AS regardless of surgical risk.
Key advantages of TAVR include:
- No sternotomy or cardiopulmonary bypass in most cases
- Procedure performed under local anesthesia with sedation in many centers
- Hospital stay of 2–3 days
- Rapid recovery — most patients return to normal activity within 1–2 weeks
Shanghai's structural heart disease programs — particularly at Zhongshan Hospital and Ruijin Hospital — are among the highest-volume TAVR centers in China, with extensive experience in both transfemoral and alternative access approaches. Chinese-developed TAVR devices (VenusA, J-Valve) are also available alongside international platforms (Edwards SAPIEN, Medtronic Evolut).
Transcatheter Mitral and Tricuspid Interventions
Catheter-based therapies for mitral and tricuspid valve disease are an active and rapidly evolving field:
- MitraClip / TEER (Transcatheter Edge-to-Edge Repair): A clip is delivered via catheter through the femoral vein and across the atrial septum to grasp and approximate the mitral valve leaflets, reducing regurgitation. Approved for both primary and secondary MR. The COAPT trial demonstrated significant mortality and heart failure hospitalization reduction in secondary MR patients treated with MitraClip on top of optimal medical therapy.
- Percutaneous Mitral Balloon Valvuloplasty (PMBV): For rheumatic mitral stenosis with favorable valve morphology, a balloon catheter is used to split the fused commissures and enlarge the valve orifice. A highly effective, minimally invasive alternative to surgery for suitable patients.
- Transcatheter Tricuspid Interventions: Multiple devices are in clinical use or trials for tricuspid regurgitation, including TEER devices (TriClip, CLASP) and transcatheter tricuspid valve replacement systems.
Concomitant Procedures
Valve surgery is frequently combined with other cardiac procedures performed during the same operation:
- Coronary Artery Bypass Grafting (CABG): If significant coronary artery disease is present, bypass grafting is performed simultaneously to avoid a second operation.
- Atrial Fibrillation Ablation (Cox-Maze procedure): Many patients with valve disease develop atrial fibrillation. The surgical Maze procedure — creating a pattern of lesions in the atrial tissue to eliminate AF — can be performed concomitantly, with success rates of 70–90% for freedom from AF at 5 years.
- Left Atrial Appendage Closure: To reduce stroke risk in patients with AF, the left atrial appendage (the primary source of AF-related thrombus) can be ligated or clipped during surgery.
- Aortic Root Replacement: If the aortic root is dilated (as in Marfan syndrome or bicuspid aortic valve disease), root replacement (Bentall procedure or valve-sparing root replacement) may be performed alongside valve surgery.
Recovery and Rehabilitation
Recovery timelines vary by procedure type:
- TAVR: Hospital stay 2–3 days. Most patients are mobile within 24 hours. Return to normal activity within 1–2 weeks. Patients can typically fly home within 1–2 weeks of the procedure.
- Minimally invasive valve surgery: Hospital stay 5–8 days. Return to light activity in 3–4 weeks. Sternal precautions not required (no sternotomy). Long-haul travel typically feasible at 3–4 weeks post-discharge.
- Open valve surgery (sternotomy): Hospital stay 7–12 days. Sternal healing requires 6–8 weeks of activity restrictions. Long-haul travel typically feasible at 6–8 weeks post-discharge.
Cardiac rehabilitation — a structured program of supervised exercise, education, and risk factor management — is recommended after all valve interventions and is available at Shanghai's major cardiac centers.
What Medical Records Are Required
To facilitate a specialist consultation or pre-operative assessment in Shanghai, patients should prepare:
- Recent echocardiogram report and images (TTE and/or TEE, ideally within 3–6 months)
- Cardiac CT report and images (particularly for TAVR candidates)
- Coronary angiography report (if performed)
- ECG (12-lead)
- Cardiac MRI report (if performed)
- Summary of symptoms, functional status (NYHA class), and disease duration
- Complete medical history including comorbidities (diabetes, renal function, lung disease)
- Current medication list including anticoagulants and antiplatelet agents
- Prior cardiac surgery or intervention records
Cost Reference
Indicative costs for valve procedures in Shanghai:
- Specialist cardiology consultation: USD 150–400
- Transthoracic echocardiogram: USD 150–350
- Cardiac CT (TAVR planning): USD 400–800
- TAVR procedure (including device and hospital stay): USD 25,000–45,000
- Open aortic valve replacement (mechanical or biological): USD 15,000–28,000
- Minimally invasive mitral valve repair: USD 18,000–35,000
- Combined valve + CABG surgery: USD 22,000–40,000
These figures are indicative. A detailed cost estimate requires review of individual medical records and planned procedure scope.
Frequently Asked Questions
How do I know if I need valve surgery or a transcatheter procedure?
The choice depends on your valve pathology, anatomy, age, surgical risk, and the expertise available at the treating center. A Heart Team — comprising cardiac surgeons, interventional cardiologists, imaging specialists, and anesthesiologists — reviews each case collectively to recommend the optimal approach. Shanghai's leading cardiac centers operate formal Heart Team programs.
I have been told I am too high-risk for open surgery. Are there options in Shanghai?
Yes. TAVR, MitraClip, and other transcatheter interventions are specifically designed for patients who are high-risk or inoperable for conventional surgery. Shanghai's structural heart programs have extensive experience with these procedures in complex, high-risk patients.
How long will I need to stay in Shanghai?
For TAVR: plan for approximately 2–3 weeks total (pre-operative workup, procedure, recovery, and clearance for travel). For open or minimally invasive surgery: plan for 4–6 weeks minimum, depending on recovery progress.
Will I need anticoagulation after my procedure?
This depends on the type of valve implanted and whether you have atrial fibrillation. Mechanical valves require lifelong warfarin. Biological valves and TAVR typically require only 3–6 months of anticoagulation or antiplatelet therapy in the absence of AF. Your cardiologist will provide a specific post-procedure anticoagulation plan.
Planning Your Cardiac Care in Shanghai
If you have been diagnosed with heart valve disease and would like to explore surgical or transcatheter treatment options in Shanghai, China Medical Concierge (CMCS) can coordinate your specialist consultation, pre-operative workup, hospital placement, and travel logistics. Contact us for a confidential initial review.
댓글 0개